Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRY
DateTimeSourceHeadlineSymbolCompany
17/05/202400:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
10/05/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202423:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202421:05GlobeNewswire Inc.ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
30/04/202414:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
03/04/202414:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
21/03/202420:05GlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202421:05GlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202417:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
06/03/202414:01GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
02/03/202401:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
29/02/202402:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202417:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202414:01GlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
22/02/202414:01GlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
20/02/202414:01GlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
05/02/202414:01GlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
04/01/202421:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
04/01/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
04/01/202421:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
04/01/202421:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202321:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202321:00GlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202316:02GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202314:57Dow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202314:03GlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
03/10/202314:03GlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
25/09/202321:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202315:20Dow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SPRY

Your Recent History